{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:13Z","timestamp":1747181113215,"version":"3.40.5"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,20]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Membranous nephropathy (MN) is an autoimmune disease, which is classified into primary and secondary MN. Malignancy-associated MN (M-MN) accounts for about 10% of secondary MN cases. Lung cancer is the most common type of malignancy among M-MN patients. Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) have showed promising efficacy and good safety in many types of solid tumors, including non-small cell lung cancer. To date, whether ICIs could be a treatment option for M-MN patients with PD-L1 expression and or high tumor mutation burden (TMB) level has not been documented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 68-year-old male patient presented with edema of the lower limbs with increased urine foam in August 2018. Biopsy on the right kidney showed MN at stage I with subepithelially localized immune deposits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Lung squamous cell carcinoma (LSCC)-associated MN with PD-L1 expression (20%) and high TMB level (26.2 mutations\/Mb).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received immunosuppressive therapy targeting the initially diagnosed primary MN as first-line treatment plus surgery and radiochemotherapy following pembrolizumab targeting the definitively diagnosed lung cancer as second-line treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient benefited from radiochemotherapy following pembrolizumab (lasting more than 38 months) rather than immunosuppressive therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Our work suggests that combined ICIs might be an effective treatment option for M-MN patients who harbor PD-L1 expression. Our work highlights that the presence of malignancy should not be neglected at the initial diagnosis of MN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032508","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T21:53:31Z","timestamp":1674770011000},"page":"e32508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report"],"prefix":"10.1097","volume":"102","author":[{"given":"Feifei","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwei","family":"Du","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-8153","authenticated-orcid":false,"given":"Surong","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41572-021-00310-0","article-title":"Membranous nephropathy.","volume":"7","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous nephropathy: core curriculum 2021.","volume":"77","author":"Alsharhan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000364782","article-title":"Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies.","volume":"40","author":"Leeaphorn","year":"2014","journal-title":"Am J Nephrol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors.","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.semnephrol.2010.09.011","article-title":"Membranous nephropathy and malignancy.","volume":"30","author":"Beck","year":"2010","journal-title":"Semin Nephrol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40620-018-0489-z","article-title":"Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.","volume":"31","author":"L\u2019Imperio","year":"2018","journal-title":"J Nephrol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"619147","DOI":"10.3389\/fimmu.2021.619147","article-title":"Case report: THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient.","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ckj\/sfz074","article-title":"Relapse of membranous nephropathy with cancer immunotherapy.","volume":"14","author":"Kim","year":"2021","journal-title":"Clin Kidney J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:07:00Z","timestamp":1746324420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032508","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}